SCHEMBL4157852

SCHEMBL4157852

COc1ccc2c(c1)CCc1ccccc1C2=Cc1cccc(C(N)=O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
PKM P14618 1/20 0.53
ATM Q13315 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MIF P14174 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
PARP1 P09874 1/20 0.48
NR3C1 P04150 1/20 0.47
PGR P06401 1/20 0.47
NR3C2 P08235 1/20 0.47
AR P10275 1/20 0.47
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
ABCB1 P08183 1/20 0.46
MAOB P27338 1/20 0.46
MAPK14 Q16539 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4163513 0.87 AR (0.52) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4150992 0.84 MIF (0.56) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4150994 0.84 MIF (0.56) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4157857 0.83 MAPT (0.55) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4042210 0.80 KMT2A (0.69) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4167935 0.79 MIF (0.54) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4163634 0.78 MIF (0.64) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4160979 0.78 MIF (0.53) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4160984 0.78 MIF (0.53) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4163632 0.78 MIF (0.64) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 MAPT 3591/4885NPC1 245/4885RAB9A 4500/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 MAPT 3416/4885NPC1 234/4885RAB9A 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.